Why NightHawk Biosciences Stock Is Soaring

NightHawk Biosciences Inc NHWK shares are trading higher Monday after the company said it would fund development of a monkeypox vaccine.

NightHawk executed a research and development license agreement with Lytic Solutions on Sunday.  As part of the agreement, NightHawk will fund a research program for development of a proprietary subunit monkeypox vaccine.

The Lytic platform has exhibited immunogenicity and vaccine success against other viral targets in non-human primates. NightHawk will own all monkeypox virus construct sequences conceived, developed or reduced to practice during the research program. These new constructs will be targeted against a series of proteins to formulate a polyclonal vaccine.

NightHawk is a commercial-stage company with a fully integrated ecosystem to accelerate the discovery and development of novel therapies that arm the immune system.

See Also: AMC Entertainment Stock Is Going APE Today: What's Going On?

NWHK Price Action: NightHawk has a 52-week high of $3.17 and a 52-week low of $1.60.

The stock was up 18.1% at $2.68 at press time, according to Benzinga Pro.

Photo: PublicDomainPictures from Pixabay.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: MoversTrading Ideaspremarket tradingwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!